ArticleCancers2021

Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214.

Norikazu Masuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.